Search

Expert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases

Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte  Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.

Read more

EHA joins ESMO in calling for EU action on shortages of essential medicines

EHA joins ESMO in calling for EU action on shortages of essential medicines

The European Hematology Association (EHA) has endorsed and signed a collective Call to Action, prepared by the European Society for Medical Oncology (ESMO), on shortages of inexpensive, essential…

Read more

EHA Blood Cancer Awareness Month Wrap-up

The first European Hematology Association (EHA) Blood Cancer Awareness Month digital campaign aimed to raise awareness of hematological malignancies and EHA’s commitment “towards a cure for all blood disorders”.

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

3rd Highlights of Past EHA (HOPE) in 2020 focused on Latin America a success!

November 13, 2020

Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof G Stemmelin (Argentinian Society of Hematology)

On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second HOPE Latin America meeting in a virtual format.

Read more

H-Net, the European Network for Harmonization of Training in Hematology, and its policy

H-Net, the 3-year European Network for Harmonization of Training in Hematology project led by Professor Eva Hellström-Lindberg, ended in September 2011, but its strongest components continue.

Read more

Publications

Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Read more

Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland

The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…

Read more